Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06188702 · ClinicalTrials.gov registry record · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
A Phase 1 study of MTAP-deleted Solid Tumors, sponsored by Servier Bio-Innovation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 342
- Enrollment target
- 20
- Study locations
NCT06188702 is a Phase 1 study of MTAP-deleted Solid Tumors that is actively recruiting participants, run by Servier Bio-Innovation. The registered enrollment target is 342 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT06188702, a Phase 1 study of MTAP-deleted Solid Tumors, is actively recruiting participants, sponsored by Servier Bio-Innovation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 342 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor. TNG462 is a protein arginine N-methyltransferase 5 \[PRMT5\] inhibitor.
Conditions Studied
Interventions
- DRUG S095035
- DRUG TNG462
Study Locations (20)
Other
- Townsville University Hospital - Douglas
- Royal Hobart Hospital - Hobart
- University Hospital Rigshospitalet - Copenhagen
- Odense Universitets Hospital - Odense
- Institut Bergonié - Bordeaux
- Centre Georges-François Leclerc - Dijon
- Hôpital de la Timone (Marseille) - Marseille
- Institut Gustave Roussy - Paris
- Charite Universitatsmedizin - Berlin
California
- University of California Los Angeles - Los Angeles
- University of California, San Francisco (Ucsf) School of Medicine - San Francisco
Florida
- Lake Mary Cancer Center - Florida Cancer Specialists & Research Institute - Lake Mary
Indiana
- Community Health Network - Indianapolis
Massachusetts
- Dana Farber Cancer Institue - Boston
North Carolina
- Duke University School of Medicine - Durham
Ohio
- Taylor Cancer Research Center - Maumee
Tennessee
- SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2031-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06188702
The ClinicalTrials.gov registry entry for NCT06188702 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Servier Bio-Innovation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with MTAP-deleted Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which S095035 is the first listed.
NCT06188702 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06188702 about?
NCT06188702 is a clinical study titled "S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP". This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatmen...
What is the current status of trial NCT06188702?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 342 participants. The study started on 2024-04-29. Estimated completion is 2031-10-31.
What conditions does trial NCT06188702 study?
This clinical trial studies the following conditions: MTAP-deleted Solid Tumors.
What interventions are being tested in trial NCT06188702?
The interventions under investigation include: S095035 (DRUG), TNG462 (DRUG).
Who is sponsoring clinical trial NCT06188702?
This trial is sponsored by Servier Bio-Innovation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06188702 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MTAP-deleted Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.